Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Trial details
- Registry ID
- NCT07620574
- Drugs studied
- Abiraterone, Atezolizumab, Cabozantinib, Enzalutamide and 3 more
TrialRedline tracks 14 clinical trials sponsored by Exelixis: 7 Phase 3, 2 Phase 2 / 3, 5 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine TumorsNCT06943755 | Everolimus, Zanzalintinib | Recruiting | 2029-06-30Estimated |
| Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNCT06082167 | Pembrolizumab, Zanzalintinib | Active not recruiting | 2028-08Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of Zanzalintinib in Participants With Recurrent or Progressive MeningiomaNCT07428616 | Zanzalintinib | Recruiting | 2028-02-29Estimated |
| Study of Cabozantinib (XL184) in Adults With Advanced MalignanciesNCT00940225 | Cabozantinib | Completed | 2013-05Actual |
| Study of XL184 (Cabozantinib) in Adults With Glioblastoma MultiformeNCT00704288 | XL184 | Completed | 2012-06Actual |
| Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPCNCT01995058 | abiraterone, cabozantinib, prednisone | Terminated | 2014-11Actual |
| Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second RelapseNCT01068782 | Cabozantinib | Terminated | 2011-05Actual |
Names as written in the registry records.
Before: Not yet recruiting. After: Enrolling by invitation.
Before: Jul 2025. After: 15 Dec 2026.
Before: Estimated. After: Actual.
Before: May 2026. After: 16 Jun 2026.
Before: Jun 2029. After: 30 Jun 2029.
NCT07428616 · Exelixis
Before: Not yet recruiting. After: Recruiting.
NCT07428616 · Exelixis
Before: Feb 2028. After: 29 Feb 2028.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: In the Randomized Phase, to evaluate the preliminary efficacy and tolerability of multiple regimens of XL184 Measure: In the Expansion Phase, to evaluate the efficacy of XL184 treatment. After: Measure: Randomized Phase: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Measure: Expansion Phase: Objective Response Rate (ORR).
Before: Completed. After: Terminated.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Radiographic progression free survival (PFS). After: Measure: Radiographic Progression Free Survival (PFS).
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Duration of Progression Free Survival per Response Evaluable Criteria in Solid Tumors version 1.1 (RECIST 1.1) Measure: Duration of Overall Survival (OS). After: Measure: Duration of Progression Free Survival (PFS) Per Response Evaluable Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Radiology Committee (BIRC) Measure: Duration of Overall Survival (OS).
Before: 8 Mar 2021. After: 30 Nov 2021.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Duration of Progression Free Survival (PFS) for the experimental arm vs. the control arm Measure: Duration of Overall Survival (OS) for the experimental arm vs. the control arm. After: Measure: Progression Free Survival (PFS) for the Experimental Arm Versus the Control Arm in the PFS Intent to Treat (PITT) Population Measure: Overall Survival (OS) for the Experimental Arm Versus the Control Arm in the ITT Population.